TPIV is a "pos" still no updates because TPIV has nothing to tell you, New CEO needs to come clean and provide an updated list of milestones w/ deadlines the company can meet!
I want to re-post a few past messages which help tell the TPIV Story:
09/17 Post: 10 days left in Q3 2017, good time for me to provide a message posted earlier in September. Still waiting for all the good news in Q32017 just like Q32016, Q42016 , Q42015 and so on and so on. You got nothing again Glynn Wilson, prove me wrong if you got what it takes, probably not. My message from Sept 7, follows:
Do not get pressured into buying the disaster TPIV, it will just end in big economic disappointment. TPIV has positioned itself via both long term and recent performance for significant share price declines. Changes in management needed immediately or we head towards $0.50/share - $1/share. Please refer to my recent post:
TPIV BOD's recognize concerns in management performance and are working it. Although I have communicated this in the past, BOD action has nothing to do with my connections to the TPIV BOD, it has everything to do with Glynn Wilson's very poor performance and shareholder value destruction over the years. This is further complicated by the fact Wilson re-priced warrants for the 2015 private investors during the last round of financing this summer without regard to other existing shareholders. There are questions concerning the 2015 private investors selling shares and/or warrants since the 2015 financing and the downward impact on share price since that time. Combine the above activity with the very long term published interviews, management presentations, press releases and other forms of communications and promotion where milestones/commitments have been continuously amended and schedules regarding real scientific data and progress have never been met and you have the basis for SEC complaints and legal action. Throwing gasoline of the fire is the potential collateral damage from questionable relationship people associated with TPIV may have with Neurotrope (NTRP) and other entities associated with NTRP as outlined in a published SeekingAlpha article, the article mentioned TPIV. I was shocked when I read this article, why was this never communicated to TPIV shareholders. So yes much to question about TPIV management and BOD over the years and they may get to answer questions the hard way. Finally all this happened under ther reign of the current CEO, Glynn Wilson. Irrespective of legal action and complaints the above is wrong, flat out wrong and unethical, financially and emotionally destructive to people who put their trust, faith and financial future in real companies and the market. Why would any CEO or anyone get to keep their job after doing the above, but yet we have it in modern day TPIV and its CEO Glynn Wilson. What is worse, Wilson will not recognize that he failed and resign which leads me to draw conclusions to the sociopath behavior of Bernie Madoff, how can a CEO like Wilson survive. Looks like Wilson will survive at your expense. Glynn, let me educate here a bit, you never get to retire when you want to and on your terms so move on.
Now lets focus on recent performance. Here is the first paragraph from the PR Newswire release after the TPIV quarterly update on August 31:
Anticipated 2017 Milestones:
"Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200 Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer Complete enrollment in TapImmune Sponsored Phase 2 study of TPIV 200 in TNBC File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer".
There is no reference to Q317 anymore and MAYO has been completely eliminated from this summary. MAYO is now an academic institution whos does not care about TPIV or its shareholders. Really, nice of TPIV to communicate that at Quarterly Update as it appears we are late again! What about AZN Durvalumab, failed in trials earlier this year, so everything at risk here. Also, Wilson mentioned the recent financing as a big accomplishment in Q217, it was dilutive, provided preferential treatment to 2015 investors via re priced warrants, includes no real lock-up period for new investors, and millions more share potential capped at low share prices. Finally, Wilson also stated the financing was "at market", what? At market very close to 12-month and historic lows (close to $0.30/share pre-reverse split). This accomplishment just goes to show how stupid Wilson, he just does not understand business side as well, just can not execute. Wilson and TPIV have zero credibility now, how can you believe anything this company tells you.
In summary, TPIV has a big problem with MAYO, AZN Durvalumab in-house, with Celgene combo trials, and with competitors. The Quarterly Update was pathetic and all deadlines appear to be extended. I still wonder if MAYO trials are a sure thing now. I informed the message board nothing would come from TPIV and Wilson at both the annual meeting and and quarterly update last week and it turned out worse than I thought, TPIV appears to be late on everything. No Mayo influence, late again and amending trials, extending schedule and costing more money. As a result, more financing will needed sooner rather than later, more dilution will occur which equals more shareholder value destruction while risk for private investors is mitigated via additional warrant re-pricing. I would not touch this stock with 100 foot pole. Management changes needed now! This stock is going to slide down to $0.50 to $1/share reflecting cash value or less until new management is in place and real data and real progress is reported. Do not be suckered into buying this stock, you are giving your money to help protect downside for the private investors and to let village idiot remain employed. This is a complete disaster at present.
09/19 Post: shub, I think you make a point, we assume going in to the investment that management is competent, transparent, credible and driven. Unfortunately TPIV management is not and is led by a 70 year old CEO, Wilson who is a complete idiot. TPIV has never executed to schedule and/or provided any real data or progress in several years. What TPIV has done is put out extreme promotion while taking shareholder money. I just do not understand why the TPIV BOD's and large investors do not push him out. I really think everyone got too cozy. The BOD's do not care, they have a lottery ticket that may payout someday. The large investors get their warrants re-priced every time Wilson does another refinancing so these investors have no motivation to move faster or more urgently, their downside is mitigated and the opportunity to reduce long term acquisition cost is present. This is not only unethical but possibility illegal but Wilson does it, the only thing he is good at and it enables him to stay employed when he should be retired. In summary, unless we have a shake-up here which starts with replacing Wilson there will be more of the same with share price down to $1/share or lower, possible legal and regulatory action. As a result, by investing in TPIV you will not be even anymore. Good luck with other investments.
10/02 Post: We got nothing in Q3 2017 and that is "OK'??? This has happened over and over gain while we run out of cash again. Wilson told an outright lie, he should be put in jail, SEC complaints should be processed. Where in the heck is Hoang, getting paid big bucks needs to show up to work and step up, make contact. "Hope", tired of seeing stories about hope on the Internet, tired of MAYO and the nutty professor Knutson, he is just maintaining his salary and expense account on your buck. Boy Kenney appears to be a big flame-out, a true consultant! This company and stock is a real "pos"! Send the big investors a message, sell let them lose money for once, then buy back after they see some pain. See my earlier post:
TP1, Bur BP - I am not going to disclose if I have influence, however, what I do have is knowledge. We are probably dead in the water for the remainder of 2017 and this means the share price goes down because shareholders are impatient and we are burning through cash, more now with recent CEO hire added to Wilson's salary and Kenney's consulting charges just ridiculous! I do not find losing money fun or a time to make jokes, again real people losing money here, this is BS. The share price goes down either fast or painfully slow. Only thing can stop it is real data and real progress which is delayed now due to CEO change. You just can not make share price go up with a management change, doesn't matter if it is a good move or not. Right now some investor trying to support share price, when he gets tired of this and finds out another investor is exercising warrants, he will get pissed and stop and share price goes down again either fast or slow. There are warrants out there as low as $1.20/share.
Hoang the new CEO has to deliver his message, we need to know the new baseline including milestones and timing, rip off the Band-Aid. We need new status on all milestones and work like PolyStart. Hoang may need to make some personnel changes. No one seemed confident at last quarterly update, refering to MAYO as an academic institution. MAYO-Knutson stating that he wanted to get TPIV200 in lab with a combo trial, everything out of control. Wilson gives nothing on AZN and other trials, tries to shift emphasis to 2017 not Q3 2017. Wilson is out of the picture going forward, a wallflower, when his contract is up he is out. It is the new CEO Hoang's butt on the line, he could care less about Wilson, he is in charge now. You do not replace a CEO who does not want to go if everything is progressing per plan, on schedule with all milestones met and in place. Hoang will need to communicate now and not make a mistake, this is going to take time.
From what I can gather today, hiring this guy and paying him so much was a "Hail Mary" by the TPIV BOD's and the major shareholders, we are behind schedule again including possibly the AZN/MSK combo trial, maybe AZN not interested anymore. Let's pay Hoang a million dollars and see if he can turn it around, we have cash in company, better that current CEO and if we stay in the current mode we lose all our investment. Hope this guy can make the magic appear and quick, the wait again is damn frustrating. Hopefully we have something real to offer and did not waste $1,500,000 on this guy who was unemployed when he took the job. Real date, Real progress will support share price and the CEO needs to get this and fast.
10/07 Post: I read latest interview w/Hoang, my input on parts of interview follow::
"Just a few years ago, venture capitalists would have laughed ideas like TapImmune out of the room"
That is not what Wilson was professing to me personally over the years, extreme promotion was evident. There is a legal case for fraud and SEC complaints here. Throw in potential unethical BOD members and TPIV may be in trouble.
"Hoang understands his company faces an uphill battle. It is a small, publicly-traded company in a field with highly-funded giants; it is trying to upend established therapies and advance the scientific field; and it targets aggressive and difficult to treat cancers. Therefore, establishing a company culture in which all stakeholders feel that what they do matters and what the company does matters is essential, Hoang said."
This sounds much more difficult than what Wilson was professing again fraud. Hoang got his $1.5 to 2.0 Million so no risk for him. Also is company having "Culture" problems after 13 years with Wilson?
"We want to raise money sooner rather than later," he said, noting the high cost of clinical trials. "That's the number one thing on my agenda today."
This only leads to one thing "DILUTION" unless TPIV has something to report which they don't and again late, a case for fraud. Also, I guess he is conveying that Wilson performed very poorly securing financing, gave company away to unethical P.E. sharks. How long do shareholders wait until they puke up their shares and this heads to low $2's for start.
Finally, Bellicum did not start or anchor the BioTech Industry in Houston, the largest Medical Center in the world. Houston has been working for years to get BioTech started and Bellicum is a pimple on the ass of the Houston Medical scene, the guy has the potential to be a promoter, just want results now, no more BS.
In short granted Hoang needs to get his message out then quickly deliver results. If TPIV is going to be late then he needs to publish new milestones and due dates. Based on what I have just read, we just have the TPIV BS machine up and working again, where are the results to back it up and when? Same old story so far, just a trading stock to pump and dump.
